A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma

被引:15
作者
Zhao, Ming [1 ]
Rudek, Michelle A. [1 ]
Mnasakanyan, Aleksandr [1 ]
Hartke, Carol [1 ]
Pili, Roberto [1 ]
Baker, Sharyn D. [1 ]
机构
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD 21231 USA
关键词
MS-275; LC/MS/MS; pharmacokinetics;
D O I
10.1016/j.jpba.2006.08.006
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid, sensitive and selective method was developed and validated using LC/MS/MS for determination of MS-275 in human plasma. Sample preparation involved a single step liquid-liquid extraction by the addition of 0.2 ml of plasma with 5 ml acetonitrile/n-butyl-chloride. Separation of the compounds of interest, including the internal standard paclitaxel, was achieved on a Waters X-Terra (TM) C-18 (50 mm x 2.1 mm i.d., 3.5 mu m) analytical column using a mobile phase consisting of acetonitrile/ammonium acetate (pH 2.9; 2 mM)(60:40, v/v) containing 0.1% formic acid and isocratic flow at 0.15 ml/min for 3 min. The analytes were monitored by tandem-mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 0.5-100 ng/ml with values for the coefficient of determination of > 0.99. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods (< 15%). This method was subsequently used to measure concentrations of MS-275 in cancer patients receiving an oral weekly dose of 4 mg/m(2) Published by Elsevier B.V.
引用
收藏
页码:784 / 787
页数:4
相关论文
共 8 条
[1]   Rational development of histone deacetylase inhibitors as anticancer agents: A review [J].
Acharya, MR ;
Sparreboom, A ;
Venitz, J ;
Figg, WD .
MOLECULAR PHARMACOLOGY, 2005, 68 (04) :917-932
[2]   Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry [J].
Hwang, K ;
Acharya, MR ;
Sausville, EA ;
Zhai, S ;
Woo, EW ;
Venitz, J ;
Figg, WD ;
Sparreboom, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 804 (02) :289-294
[3]  
Jaboin J, 2002, CANCER RES, V62, P6108
[4]   Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells [J].
Marks, PA ;
Richon, VM ;
Rifkind, RA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1210-1216
[5]  
Pili R, 2006, J CLIN ONCOL, V24, p134S
[6]   Bioanalytical liquid chromatographic method validation. A review of current practices and procedures [J].
Rosing, H ;
Man, WY ;
Doyle, E ;
Bult, A ;
Beijnen, JH .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2000, 23 (03) :329-354
[7]   Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma [J].
Ryan, QC ;
Headlee, D ;
Acharya, M ;
Sparreboom, A ;
Trepel, JB ;
Ye, J ;
Figg, WD ;
Hwang, K ;
Chung, EJ ;
Murgo, A ;
Melillo, G ;
Elsayed, Y ;
Monga, M ;
Kalnitskiy, M ;
Zwiebel, J ;
Sausville, EA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3912-3922
[8]   A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors [J].
Saito, A ;
Yamashita, T ;
Mariko, Y ;
Nosaka, Y ;
Tsuchiya, K ;
Ando, T ;
Suzuki, T ;
Tsuruo, T ;
Nakanishi, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4592-4597